Oncology

closed shuttered shut down closed
Biotech

Adecto blames ‘risk-adverse funding environment’ for closing

Adecto’s 12-year story has come to an end as the immunotherapy biotech blamed a “risk-averse funding environment” for shutting up shop.
James Waldron Oct 2, 2026 3:53am
Genentech

Genentech inks $1.5B bispecific pact with fast-rising Earendil

Sep 25, 2026 2:51am
Robot hands with a pieces of the puzzle

Boehringer, Envisagenics ink $1B multi-target oncology collab

Sep 22, 2026 8:00am
Daniel ODay

CEO O’Day tells Fierce how Gilead reached ‘critical mass’

Sep 16, 2026 8:00am
Lab Space Frontier

After ‘tough years,’ Frontier is ramping up clinical ambitions

Aug 27, 2026 9:50am
Revolution Medicines booth at ASCO 2026
Favicon Fierce Pharma

FDA greenlights RevMed’s pancreatic cancer gamechanger

Aug 26, 2026 11:30am
More News
Fierce Pharma

McKesson acquires Maryland CRO for $2.25 billion

Aug 25, 2026 11:22am

Pheast’s CEO has no regrets despite competitors gaining an edge

Aug 21, 2026 8:00am

Merck-Moderna cancer vax slows recurrence in ph. 3 trial

Aug 19, 2026 6:45am

Merck and Sarah Cannon team up for oncology trial efficiency

Aug 18, 2026 4:00pm